Sevelamer versus calcium-based phosphate binders for chronic kidney disease

Area of Science:

• Nephrology
• Pharmacology
• Evidence-Based Medicine

Background:

• Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a common complication.
• Therapeutic options include calcium-based phosphate binders and sevelamer, a non-calcium phosphate binder.
• Clinical guidelines lack consensus on the optimal phosphate binder choice.

Purpose of the Study:

• To compare the efficacy and safety of sevelamer versus calcium-based phosphate binders in patients with CKD-MBD.
• To synthesize current evidence using meta-analysis and the GRADE approach.

Main Methods:

• Systematic search of the Epistemonikos database.
• Inclusion of 12 systematic reviews, with 41 randomized controlled trials.
• Meta-analysis of treatment effects and GRADE assessment of evidence certainty.

Main Results:

• Sevelamer demonstrated a potential benefit in reducing hypercalcemia.
• Sevelamer was associated with a higher incidence of gastrointestinal adverse events compared to calcium-based binders.
• Evidence regarding differences in mortality between the two binder types was of very low certainty.

Conclusions:

• Sevelamer may be a viable option for managing hypercalcemia in CKD-MBD, with careful consideration of gastrointestinal side effects.
• Further high-quality research is needed to clarify the impact of phosphate binders on mortality in CKD-MBD.